Researchers studied the effectiveness of liquid biopsy testing in 9,911 women without a family history of cancer. Researchers tested each woman with the DETECT-A blood test and followed that test with PET-CT imaging, achieving a 99.6 percent specificity rate.
The blood test initially detected the following cancers: lymphomas (two), colorectal (two), appendix (one), uterine (two), thyroid (one), kidney (one), lung (nine), breast (one), ovary (six) and unknown primary (one). Seventeen of the cancers were first detected in an early stage. Standard follow-up screening detected an additional 24 cancers. When combined, cancers detected by either the blood test or standard screening accounted for more than half of the 96 cancers detected during the study.
Researchers surveyed the patients, who said the blood test did not dissuade them from also using traditional screening methods.
Lead report author Anne Marie Lennon, PhD, said, “This study suggests that a multicancer blood test can be a complementary and additive to standard of care screening and may be a good strategy for increasing early detection of cancer.”
Read the entire report here.
More articles on surgery centers:
Illinois Department of Health continues plea for surgery centers to donate PPE
Airbnb for ASCs — How a company is pairing surgeons with available surgery centers
The Joint Commission supports personal face mask use
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.